New Noninvasive Tests for Colon and Prostate Cancer Presented at the 2021 AACC Annual Scientific Meeting

Two research teams have developed new noninvasive tests that use either blood or saliva samples to diagnose cases of colorectal cancer or prostate cancer, respectively. Presented today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, these tests could facilitate screening efforts for colorectal cancer and allow clinicians to better distinguish early-stage prostate cancer from more benign prostate conditions.

Active surveillance for low-risk prostate cancer: New data on risk factors for switching to active treatment

For men with “low-risk” prostate cancer initially managed with active surveillance, cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Advancements in Prostate Cancer Treatments are Providing Better Outcomes for Men

Over the last decade, advancements have been made in the diagnosis and treatment of prostate cancer that are saving more lives. Tina Mayer, MD, a medical oncologist in the Prostate Cancer Program at Rutgers Cancer Institute of New Jersey shares some insight.

Mount Sinai researchers develop novel therapy that could be effective in many cancers

New York, NY (July 23, 2021) — Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery , a…

Bidirectional impact of cardiovascular disease, cancer in Blacks focus of new AHA center

Cardiovascular disease and cancer, the nation’s top two killers, share common ground like obesity and chronic inflammation, as well as a disproportionate impact on Black Americans. A new American Heart Association-funded center at the Medical College of Georgia is working…

Mount Sinai Welcomes Robotic Prostate Surgery Pioneer Mani Menon, MD

Robotic prostate surgery pioneer Mani Menon, MD, is joining Mount Sinai and will serve as Chief of Strategy and Innovation in the Department of Urology for the Mount Sinai Health System. He will also serve as a Professor of Urology, Director of Education and Director of the Precision Prostatectomy Program in the Department of Urology at Icahn Mount Sinai and Center of Excellence for Prostate Cancer at The Tisch Cancer Institute.

Study Sheds Light on Persistent Racial Disparities in Prostate Cancer Care in the United States

Black men most likely to benefit from advanced prostate cancer therapies are 11 percent less likely to get them than non-Black men. This happens despite apparent equal opportunities in obtaining health care services, a new study in American veterans shows.

BET inhibitors show promise in overcoming lineage plasticity, a newly recognized form of resistance to prostate cancer drugs

In a new study, a team of researchers uncovered new mechanisms underlying an important type of resistance to modern prostate cancer drugs called lineage plasticity, where castration-resistant prostate cancers undergo a deadly identity switch. They also outline a promising path to overcoming this form of resistance: BET bromodomain inhibitors.

Rutgers Cancer Institute of New Jersey Experts Available for Comment during Men’s Health Month

New Brunswick, N.J., June 7, 2021 – June is a special time of year focused on heightening the awareness of preventable health problems and encouraging early detection and treatment of disease for men. Diseases like prostate cancer, which is the…

Mount Sinai identifies the causes of racial disparity in prostate cancer in a multi-institutional study

MEDIA ADVISORY Senior Author:  Ash Tewari, MBBS, MCh, Professor and System Chairman of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Prostate Cancer…

Cleveland Clinic Researchers Identify New Drug Target for Treating Aggressive Prostate Cancer

CLEVELAND: According to new findings published in Science Translational Medicine, Cleveland Clinic researchers have identified a promising drug target for treating and preventing aggressive, drug-resistant prostate cancer.

The team, led by Nima Sharifi, M.D., of Cleveland Clinic’s Lerner Research Institute, demonstrated that inhibiting the protein H6PD led to significantly reduced tumor sizes and improved survival among mouse models with drug-resistant prostate cancer. The H6PD levels also were elevated in biopsied patient tumors, suggesting the protein might be targeted in patients for treatment.

UVA develops new tools to battle cancer, advance genomics research

University of Virginia School of Medicine scientists have developed important new resources that will aid the battle against cancer and advance cutting-edge genomics research. UVA’s Chongzhi Zang, PhD, and his colleagues and students have developed a new computational method to…

Cleveland Clinic experts available to comment on cancer research presented at ASCO Annual Meeting

Cleveland Clinic cancer researchers are involved with more than 50 studies that’ll be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, June 4—8, 2021. Key research from Cleveland Clinic focuses on advancements in the prevention and…